



Spatial variation of pharmaceutical concentrations in the River Almond



EU noPILLS project

- Funded by Interreg IV B
- 6 partners in 5 countries
- Aim: To reduce pharmaceutical pollution in the environment
 - Technical solutions: wastewater treatment
 - Societal solutions: reducing input of pharmaceutical residues via behaviour change
 - Increase understanding of sources and pathways

Selection of study catchment

- UKWIR-CIP results for some of the STW:
 - Low environmental dilution
 - High effluent concentrations
- Catchment characteristics:
 - Highly urbanised
 - Sewer system overstretched with multiple CSOs




River Almond





River Almond Catchment

Schematic representation showing wastewater treatment works and sampling points in River Campaign




WWTP (Capacity in PE)

0-200 PE

200-10,000 PE

10,000-50,000 PE


> 50,000 PE



Sampling point

Specific objectives

- To build up a general understanding of concentrations in the catchment
- To investigate long range (10km) transport of pharmaceutical pollutants
- To investigate the effect of dilution by a tributary
- To investigate the effect of a large WWTP




Sampling and analysis

- Sampling
 - 4 consecutive days in June 2014
 - Characterised by dry weather and low flows
 - Daily grab samples & flow measurements
 - Flow estimation via relative catchment size
- Analysis
 - LC-MS/MS (Thermo Fisher Scientific Q Exactive Quadrupole Orbitrap mass spectrometer)
 - Deuterated internal standards used where available



Overview of results (mean values)



'Sense check'

	Expected daily load (mg/day)	Measured daily load (mg/day)
Atenolol	4404	3802
Bezafibrate	285	133
Carbamazepine	195	462
Clarithromycin	916	503
Lidocaine	-	216

- All values within a factor 3 of prediction
- Prediction based on national average prescriptions (2012-13 NHS data), excretion data and removal data from literature
- Measured data are concentrations in daily grab samples x measured flow at Loc2



Environmental risk

$$RQ = \frac{PEC}{PNEC}$$

PEC = Measured environmental concentration

PNEC = Predicted no-effect concentration

High risk: $RQ > 1$

Moderate risk: $1 > RQ > 0.1$



Low risk: $RQ < 0.1$





Spatial and Temporal Variation

Atenolol (PNEC = 30 μ g/l) (4 days, 7 locations)





Bezafibrate (PNEC = 0.46 μ g/l)



Spatial and Temporal Variation


Carbamazepine (PNEC 0.42 µg/l)



Clarithromycin (PNEC 0.07 µg/l)




Spatial and Temporal Variation




Lidocaine

River Almond





River Almond Catchment



WWTP (Capacity in PE)




0-200 PE

200-10,000 PE

10,000-50,000 PE

>50,000 PE
Sampling point


Upstream and downstream from large STW (PE=60,000)




Mean concentrations increase by a factor 1.5 to 6

Concentrations Breich Water


(µg/l)



(µg/l)



(µg/l)




←10km→

- Atenolol 
- Bezafibrate 
- Carbamazepine 
- Clarithromycin 
- Lidocaine 

Calculated Loads Breich Water


mg/day



Loc1:

Upstream from STW
(flow based on
measurement at
Loc2)


mg/day



Loc2:

0.4km downstream
from STW
Based on measured
flow

mg/day




Loc3:

10km downstream from STW
Based on flow estimated
from relative catchment size

← 10km →



Controlled Activity Regulations (CAR) Authorisations



Summary

- Many of the compounds are present at (chronic) toxic levels ($RQ>0.1$)
- Significant rise in concentration after addition of WWTP discharge
- Suspected additional inputs from non-point sources

Future work

- Confirm results (sampling campaign planned for June '15)
- Investigate possible diffuse sources or minor point sources
- Repeat in wet weather (influence of CSO)



Thank you for your attention

www.no-pills.eu

Karin.Helwig@gcu.ac.uk





Toxicity and Persistency

Compound	PNEC ($\mu\text{g/l}$)	Reference	Removal in WWTP (Verlicchi et al., 2012)
Atenolol	30	Boillot (2008), in: Verlicchi et al., 2012	38
Bezafibrate	0.46	Isidori et al., 2007	61
Carbamazepine	0.42	Ferrari et al., 2003	18
Clarithromycin	0.07	Boillot (2008), in: Verlicchi et al., 2012	40
Lidocaine	nd		nd



Defined Daily Doses of the investigated drugs

Drug	DDD
Atenolol	75mg
Bezafibrate	600mg
Carbamazepine	1000mg
Clarithromycin	500mg
Lidocaine	n/a

References

- Ferrari, B., Paxeus, N., Lo Giudice, R., Pollio, A., Garric, J. (2003) *Ecotoxicological impact of pharmaceuticals found in treated wastewaters: study of carbamazepine, clofibric acid, and diclofenac.* Ecotoxicology and Environmental Safety 55, pp 359-370
- Isidori, M., Nardelli A., Pascarella, L., Rubiono, M., and Parrella, A. (2007) *Toxic and genotoxic impact of fibrates and their photoproducts on non-target organisms.* Environmental International 33: 635-641
- Verlicchi, P., Al Aukidy, M., Zambello, E. (2012) *Occurrence of pharmaceutical compounds in urban wastewater: removal, mass load and environmental risk after a secondary treatment – a review.* Science of the Total Environment 429, pp. 123-155